Simplifying Patient Access, Enhancing Care
The Sancuso Patient Rx Solutions™ program provides concierge HCP and Patient service offerings to help initial and continued access to Sancuso
What is Sancuso Patient Rx Solutions™?
With Patient Rx Solutions™ you can help ensure your patients receive prevention of chemotherapy-induced nausea and vomiting they require through access services such as:
Patch Replacement
If chemotherapy is delayed or canceled or your patient’s patch falls completely off, we may be able to help obtain a replacement patch
Copay Assistance
Copay card available that can save patients money on their SANCUSO prescription
Prior Authorization Assistance
If your patients have prescription insurance coverage, Patient Rx Solutions™ administrators provide PA services to assist with getting your patient started on SANCUSO (see enrollment below)
Patient Assistance
Our team will help eligible uninsured patients explore non-Patient Rx Solutions™ coverage options for SANCUSO
Medical Information Requests/In-Services
When your office wants to know more details about SANCUSO
Adverse Events
To report and adverse event call (615)425-7642
Contact Free Solutions: Access SANCUSO by e-prescribing through a specialty pharmacy based on your patient’s individual insurance to have SANCUSO sent directly to your patient’s home
Contact Free Solutions
Access SANCUSO by e-prescribing through a specialty pharmacy based on your patient’s individual insurance to have SANCUSO sent directly to your patient’s home
Patient Rx Solutions™
Customer Support Services
Patient Rx Solutions™ Prior Authorization Enrollment is Now Easy as 1, 2, 3
Enroll
To get started, click the button below from any digital platform (computer, tablet or smartphone) and complete a brief enrollment form
Track
During processing, receive updates of your prior authorizations and approvals via [email protected]
Fulfill
Once approved, you will be alerted that the Sancuso you prescribed will be shipped directly to your patient’s home, your practice, or dispensed from the pharmacy of your choice
Simplifying Patient Access
and Enhancing Care
INDICATIONS AND USAGE
SANCUSO (granisetron transdermal system) is indicated for the prevention of nausea and vomiting in adults receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
SANCUSO is contraindicated in patients with known hypersensitivity to granisetron or to any of the components of the transdermal system.
WARNINGS AND PRECAUTIONS
PROGRESSIVE ILEUS AND GASTRIC DISTENTION: Sancuso may mask a progressive ileus and/or gastric distention. This should be particularly considered before use of Sancuso in patients who have had recent abdominal surgery. Monitor for decreased bowel activity, particularly in patients with risk factors for gastrointestinal obstruction.
SEROTONIN SYNDROME: The development of serotonin syndrome has been reported with 5-HT3 receptor antagonists. Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of sancuso and other serotonergic drugs. If symptoms of serotonin syndrome occur, discontinue Sancuso and initiate supportive treatment. Patients should be informed of the increased risk of serotonin syndrome, especially if Sancuso is used concomitantly with other serotonergic drugs.
SKIN REACTIONS: In clinical trials with Sancuso, application site reactions were reported that were generally mild in intensity and did not lead to discontinuation of use. The incidence of reactions was comparable with placebo. If severe reactions, or a generalized skin reaction occur (e.g., allergic rash, including erythematous, macular, papular rash or pruritus), remove the Sancuso transdermal system.
INCREASED DRUG EXPOSURE WITH USE OF EXTERNAL HEAT SOURCES: Prolonged exposure to heat results in increasing plasma concentrations of granisetron during the period of heat exposure. Do not apply a heat pad or heat lamp over or in the vicinity of the Sancuso transdermal system and avoid extended exposure to heat.
PHOTOTOXICITY WITH ULTRAVIOLET LIGHT EXPOSURE: Granisetron may be affected by direct natural or artificial sunlight, including sunlamps. An in vitro study using Chinese hamster ovary cells suggests that granisetron has the potential for photogenotoxicity. To avoid a potential skin reaction, advise patients to cover the application site of the transdermal system with clothing if there is a risk of exposure to direct natural or artificial sunlight throughout the period of wear and for 10 days following its removal.
ADVERSE REACTIONS
The most common adverse reaction (≥ 5%) is constipation.
You are encouraged to report suspected adverse reactions to Cumberland Pharmaceuticals, Inc. at 1-833-Sancuso or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Have Questions or Would like to Stay Informed About Sancuso?
We’re Here to Help!
Have Questions or Would like to Stay Informed About Sancuso?
We’re Here to Help!
